Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

czyli wszystkie giełdy bardziej rozwinięte niż GPW
slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 28 lip 2021 22:55

GSK more upbeat on profits and COVID, investors not sure

(Reuters) -GSK forecast 2021 earnings at the better end of its guidance range on Wednesday, buoyed by a recovery in routine visits to doctors and sales of its COVID-19 vaccine booster that helped the drugmaker beat second-quarter profit expectations.

But rising debts, lingering effects of the pandemic and longer-term worries about the British company's drugs pipeline saw its shares hand back initial gains.

Despite being the world's biggest vaccine maker by sales, GSK has fallen behind some rivals in combatting COVID-19, focusing on producing an adjuvant to boost the immune response of others' shots rather than making its own vaccine.

After a project with Sanofi (NASDAQ:SNY) fell short of hopes last year, GSK reported progress in the second quarter, with 258 million pounds ($358 million) in adjuvant sales. The duo's vaccine is now in late-stage trials and they hope for approvals by the end of the year.

GSK and U.S. partner Vir also announced a deal to supply their antibody-based treatment for COVID-19 to the European Union.

The British company, which is spinning off its consumer health arm to focus on improving its pharmaceuticals business with incoming funds, said it was hopeful of the positive momentum running into the second half, pushing full-year earnings towards the better end of its forecast range.

GSK has said it expects adjusted earnings will decline by a mid to high-single digit percentage this year, not including any COVID-related sales.

But some analysts remained concerned about the challenges ahead, with Hargreaves Lansdown (LON:HRGV)'s Nicholas Hyett pointing to "poor levels of cash generation" and rising debt.

And while Citi analysts noted "upside potential" to full-year earnings guidance, they said their focus remained on GSK's pipeline of new drugs.

Pressure to show sustainable growth has mounted on Walmsley after years of underperformance at the pharmaceuticals business. GSK has also locked horns with activist investor Elliott over its future after the planned spin-off next year.

GSK shares, which lost a quarter of their value in 2020, were down about 1% at 1,386.2 pence by 1240 GMT, after initially rising as much as 2% on the results.

A 49% jump in vaccine sales to 1.57 billion pounds and growth in newer medicines helped GSK post adjusted quarterly earnings of 28.1 pence per share, blowing past analysts' estimate of 19.9 pence. Overall sales of 8.1 billion pounds were also ahead of a 7.56-billion-pound consensus https://www.gsk.com/en-gb/investors/ana ... -consensus.

However, GSK forecast revenues from vaccines over the full year would be broadly flat, even as some markets such as the United States open up to routine vaccinations, because COVID-19 inoculation rates are lagging in other parts of the world.

https://www.investing.com/news/economy/ ... at-2570508
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

REKLAMA


slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 01 paź 2021 10:07

GlaxoSmithKline inks ~$280M contract for US Army

Sep. 30, 2021 5:34 PM ETGSKBy: Manshi Mamtora, CFA2 Comments
GlaxoSmithKline (NYSE:GSK) was awarded a $279.86M firm-fixed-price contract for procurement, storage, and distribution of company's monoclonal antibody therapeutic treatment Sotrovimab.
Work will be performed in Durham, North Carolina, with an estimated completion date of May 19, 2022.
U.S. Army Contracting Command is the contracting activity.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 11 paź 2021 11:29

Elliott Investment boss again questions GSK on value creation - Bloomberg
Oct. 08, 2021

Gordon Singer, who heads Elliott Investment Management’s London office, took GlaxoSmithKline (GSK +0.1%) to task yesterday during a call with top shareholders over what he considers a lack of value creation, Bloomberg reports.
Board Chairman Jonathan Symonds said GSK remains committed to separating the consumer business from the pharmaceutical and vaccines business, and defended CEO Emma Walmsley, who has been criticized by Elliott in the past.
The split is planned for mid 2022.
GSK plans to name a chair of the consumer business by the end of the year.
In July, Elliott sent a letter to the GSK board outlining recommendations to boost the company's value.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 27 gru 2021 10:09

AE Wealth Management LLC boosted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 29.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 84,019 shares of the pharmaceutical company’s stock after purchasing an additional 18,896 shares during the period. AE Wealth Management LLC’s holdings in GlaxoSmithKline were worth $3,210,000 as of its most recent SEC filing.

https://etfdailynews.com/news/ae-wealth ... c-nysegsk/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 07 sty 2022 11:25

GlaxoSmithKline, Vir increases supply of COVID-19 antibody therapy to Canada to 20,000 doses

GlaxoSmithKline PLC GSK, -0.53% announced Thursday an agreement to supply the Government of Canada with 20,000 doses of Sotrovimab, the COVID-19 monoclonal antibody therapy the company developed with Vir Biotechnology Inc. VIR, . The agreement follows Canada's initial order of 10,000 doses of Sotrovimab announced in October, which included options for additional purchases. Sotrovimab was authorized for injection by Health Canada in July 2021 to treat mild to moderate COVID-19 in adults and adolescents 12 years old and older who are at high risk for hospitalization and death. Glaxo's stock slipped 0.1% in afternoon trading and Vir shares eased 0.1%, while the S&P 500 SPX, -0.10% gained 0.1%.

https://www.marketwatch.com/story/glaxo ... quote_news
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 17 sty 2022 20:36

GlaxoSmithKline (GSK) Rejects Unilever £50B Offer for Consumer Healthcare Unit

https://www.tipranks.com/news/glaxosmit ... hcare-unit
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 09 lut 2022 10:52

GlaxoSmithKline (LON:GSK) stock rose 0.5% after beating quarterly forecasts, boosted by hefty Covid-related sales, largely for antibody drug sotrovimab. The British drugmaker said it expected pandemic-related sales in 2022 to be at similar levels to 2021 but said these would contribute less to profit due to lower margins on its antibody treatment.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 13 kwie 2022 15:00

Koncern farmaceutyczny GlaxoSmithKline (GSK) przejmie firmę biotechnologiczną Sierra Oncology w ramach transakcji gotówkowej o wartości 1,9 mld USD - informuje Reuters.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 06 cze 2022 12:29

GSK (LON:GSK) stock rose 0.1% after the drugmaker’s vaccine, Priorix, was approved by the U.S. Food and Drug Administration for the prevention of measles, mumps, and rubella in those aged one year and above.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 10 cze 2022 10:47

GSK (LON:GSK) stock rose 1.6% after the drugmaker said its vaccine targeting a respiratory virus in older adults each year delivered positive results in a trial.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 18 lip 2022 09:42

Haleon is set to start trading as an independent, listed company, after GSK (LON:GSK) shareholders approved the demerger of its consumer health-care business.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 28 lip 2022 09:55

GSK plc Earnings Beat, Revenue Misses In Q2
18 hours ago (Jul 27, 2022 09:21AM ET)

Investing.com - GSK plc reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.

GSK plc announced earnings per share of £0.347 on revenue of £6.93B. Analysts polled by Investing.com anticipated EPS of £0.2642 on revenue of £7.22B.

GSK plc shares are up 7.9% from the beginning of the year, still down 4.98% from its 52 week high of £1,842.76 set on July 6. They are outperforming the STOXX 600 which is down 12.2% from the start of the year.

GSK plc shares lost 0.23% in intra-day trade following the report.

GSK plc follows other major Healthcare sector earnings this month
GSK plc's report follows an earnings missed by Renalytix AI on June 30, who reported EPS of £-0.2 on revenue of £812K, compared to forecasts EPS of £-0.0863 on revenue of £2.02M.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 12 sie 2022 12:26

GSK Shares Inch Higher After Slumping on Heartburn Drug Litigation Worries

Investing.com -- Shares in GSK plc (LON:GSK) rose on Friday, paring back some heavy recent losses, as the British pharmaceutical giant responded to a bout of speculation around lawsuits over the heartburn drug Zantac.

GSK shares moved higher by over 3%, after slumping by more than 10% since the end of trading on Tuesday.

The company said on Thursday that in-house research, as well as studies from the U.S. Food & Drug Administration and the European Medicines Agency, have all found no evidence of a causal link between ranitidine - the active ingredient in Zantac - and the development of cancer in patients.

Zantac was the world's top-selling medicine in 1988 and become one of the first to have annual sales worth more than $1B, according to Reuters.

Concerns around the treatment gained traction in 2018 after years of marketing by several drugmakers, including GSK and rivals Sanofi SA (EPA:SASY) and Pfizer (NYSE:PFE). Sanofi recalled the compound from the U.S. in 2019 following the start of an FDA investigation into the level of nitrosodimethylamine, or NDMA - which has been found to lead to cancer in humans - in it.

The FDA concluded that the drug did have a high amount of the chemical and subsequently requested it be taken off the market in 2020.

More than 2,000 personal injury cases purporting a connection between Zantac and cancer have been filed, with claimants accusing - among others - GSK, Sanofi and Pfizer of not adequately warning customers. The first trial over one of these cases is set to begin in the U.S. state of Illinois later this month.

"It seems very possible parties [...] will incur the risk of some degree of shared liability with the only real questions being what that magnitude of liability may be and when the market feels it can get a handle on it," Barclays analysts said in a note.

"Precedents would suggest a high five/low six figure average settlement per case in these types of product tort cases, implying a shared liability (based on precedent and extrapolation of present caseload) in the $5-10bn range."

Sanofi shares edged higher on Friday after they had fallen sharply throughout the week. Pfizer have also seen U.S.-listed shares slide, along with GSK's consumer health spin-off Haleon plc (NYSE:HLN), which warned in a prospectus last month that it is not yet able to assess the liability it has in any Zantac lawsuits.

A Pfizer spokesperson told Reuters that the company had not sold the product in more than 15 years and "did so only for a limited period of time."

Meanwhile, Haleon said it was "not a party to Zantac litigation proceedings," adding that it never sold the product in the U.S. as neither Haleon nor GSK Consumer Healthcare.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 13 paź 2022 12:33

GSK: Trials for Respiratory Virus Vaccine "Positive"

Investing.com -- GlaxoSmithKline plc (LON:GSK) has announced that its vaccine for respiratory syncytial virus for adults aged 60 and above showed overall efficacy of 82.6%, beating the results of a treatment made by rival Pfizer (NYSE:PFE).

GSK called the outcome of a phase III trial of its RSV vaccine candidate "positive," adding that the drug could be particularly impactful for populations most at risk of the severe outcomes of the virus, which attacks the respiratory tract and can be serious for older adults as well as infants. In severe cases, the pharmaceutical firm said, the vaccine was 94.1% effective against lower respiratory tract disease.

"These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research," said GSK chief scientific officer Tony Wood in a statement.

"We believe that with the high vaccine efficacy demonstrated in this pivotal trial, our vaccine candidate has the potential to help reduce the significant global burden of RSV-associated disease in older adults, including those at the greatest risk of severe outcomes due to their age or underlying comorbidities."

The results come after a trial of a similar vaccine from U.S. peer Pfizer demonstrated effectiveness of 66.7%, although the studies were not performed in exactly the same manner.

GSK and Pfizer, along with fellow drugmakers Johnson & Johnson (NYSE:JNJ) and Moderna (NASDAQ:MRNA), have been pushing to roll out a RSV vaccine, with analysts estimating that the market for it could one day be worth as much as $6B.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Glaxo Smith Kline LSE&NYSE: GSK p. farmaceutyczny

Postautor: slayer74 » 13 lis 2022 00:11

'Uncertain times ahead': GlaxoSmithKline stock falls 4% as UBS moves to Sell

Shares of GlaxoSmithKline (NYSE:GSK) are trading more than 4.5% lower in pre-market U.S. trading today after UBS analysts downgraded to Sell from Neutral as the pharma giant faces “uncertain times.”

The new price target on the London-listed GSK stock is £13.00 (£1 = $1.1728), down from the prior £18.20, as UBS believes GSK’s valuation is too high. Moreover, the analysts see an “unattractive earnings scenario” after 2026.

“We see two factors posing risks to the earnings base longer term - blockbuster vaccine Shingrix will exhaust its catch-up patient pool in the U.S. around '27 and HIV product dolutegravir faces patent expiry at the same time,” the analysts wrote in a client note.

These two issues could erase about 20% of revenue for GSK. If the management decides to soften 2027 bottlenecks, this “could mean earnings dilution.”

“And if GSK takes a wait and see approach to the HIV conversion strategy and waiting for improved R&D productivity, that could imply meaningful earnings risk longer term,” the analysts added.

As of 14:25 GMT, London-listed GSK shares are down about 5%.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!


Wróć do „Zagranica”

REKLAMA

Kto jest online

Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 19 gości